Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 13
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Immunovant Inc
IMVT
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$29.27
-0.21
-0.71%
Últ. Act.: Oct 13, 12:02 PM
$29.00
-0.48
-1.63%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Immunovant Financials
Immunovant (IMVT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 5.63 percent decrease over losses of $(0.71) per share from the
Benzinga Newsdesk
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.
Avi Kapoor
Immunovant Stock Surges Despite Disappointing Earnings Miss
Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss.
Evette Mitkov
Earnings Scheduled For May 20, 2026
Benzinga Insights
PRO
Immunovant Q4 EPS $(0.73) Misses $(0.60) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.60) by 21.67 percent. This is a 14.06 percent decrease over losses of $(0.64) per share from the
Benzinga Newsdesk
PRO
Immunovant Q3 EPS $(0.61) Beats $(0.71) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.71) by 13.72 percent. This is a 19.74 percent increase over losses of $(0.76) per share from the
Benzinga Newsdesk
